Journal of Hematology & Thromboembolic Diseases
Open Access

Pathophysiology and Morphological Features of Sideroblastic Anemia

Demetriou Valois^{* *}Correspondence: Demetriou Valois, Department of Health Science, Ain Shams University,Cairo, Egypt, Email:

Author info »

Introduction

Sideroblastic Anemias (SAs) are a group of inherited and acquired bone marrow diseases characterised by abnormal iron accumulation in the mitochondria of erythroid precursors. The abnormal, iron-rich mitochondria that give rise to the ring (or ringed) sideroblast, a morphological feature unique to SAs, appear to encircle the nuclei of erythroblasts. The molecular genetic basis of the SAs, which were first identified in the 1940s and codified as a class of anaemia in the 1960s, has evolved with technological advancement. More than two-thirds of cases of Congenital SA (CSA) and an even higher percentage of cases of acquired clonal disease can now be attributed to mutations in a particular gene, solid-state genotyping technologies, and Next- Generation Sequencing (NGS) over the past 30 years. This review focuses on the genetics underlying these conditions and how understanding these flaws can help in the development and application of logical treatments.. Even though many have been connected to pathways shared by the CSAs, it does not account for the large number of acquired SAs brought on by toxic and metabolic disorders that are not believed to have a genetic component.

Morphological features

• A peripheral blood smear stained with May-Gruenwald- Giemsa (MGG) and showing hypochromia, anisocytosis, and microcytosis in a man with mild XLSA.

• A siderocyte is highlighted in a patient's iron-stained peripheral blood smear (arrow).

• A peripheral blood smear stained with MGG from the patient's mother displaying the dimorphic red blood cell population, which includes hypochromic microcytes with Pappenheimer bodies (arrow).

• Iron-stained bone marrow aspirate X-Linked Sideroblastic Anemia (XLSA) showing iron granules (blue) ringed around late erythroblast nuclei.

• Transmission electron micrograph of a RARS patient displaying electron densities (black) inside deteriorating mitochondria (pale vacuoles, denoted by an arrow) ringing around erythroblast nuclei (photograph courtesy of Marcel Seiler, Boston Veterans Affairs Medical Center (VAMC), Boston, MA). (A-D) The initial magnification was 1000; all scales are equal.

Pathophysiology

Understanding heme production, the pathogenesis of sideroblastic anaemia, and the effects of faulty enzyme/transport genes are crucial. Glycine must first be carried by the mitochondrial transporter into the mitochondria by SLC25A38 before it can join succinyl-CoA. In the mitochondria, glycine and Succinyl-Coenzyme A (succinyl-CoA) combine to generate Aminolevulinic Acid (ALA), which is the first step in the synthesis of heme.

The enzyme aminolevulinic acid synthase produces ALA. After that, ALA is taken to the cytosol. Heme insufficiency and sideroblastic anaemia result from the inability to synthesise ALA because of a flaw in the enzyme ALAS2, which catalyses the process. Heme deficit is also brought on by the ABCB7 and GLRX5 mutations, although by a different mechanism, which is described below. Similar to these frequent mutations, additional genes have a variety of purposes, and when those functions aren't present, sideroblastic anaemia can result.

When one of these genes-genes on autosomal chromosomes, genes in mitochondria, and genes generating some of these enzymes-is defective, hereditary sideroblastic anaemia results. These gene mutation-related illnesses are classified as syndromic and non-syndromic.

Non-syndromic conditions include X-linked sideroblastic anaemia, also known as Sideroblastic Anaemia 1 (SIDBA1), SIDBA2, SIDBA3, and SIDBA4, while syndromic conditions include X-Linked Sideroblastic Anaemia With Ataxia (XLSA/A), Pearson's Marrow-Pancreas Syndrome (PMPS), Thiamine- Responsive Megaloblastic Anaemia (TRMA), myopathy, lactic.

Conclusion

Patients with sideroblastic anaemia tend to be younger, and their parents or guardians make health decisions on their behalf. Parents and other caregivers should become knowledgeable about this anaemia and its treatment. Patients who receive care at home should be protected against iron-rich foods that could worsen iron excess. Patients and caregivers should schedule a close follow-up check with their haematologist. It has been demonstrated that pyridoxine and perhaps iron chelation drug adherence helps patients with X-linked sideroblastic anaemia experience better healthcare results. To ensure that you are getting the right quantity of vitamins and minerals, you should adopt a balanced diet. In patients with hereditary anaemia, alcohol, isoniazid, and lead toxicity should be avoided because they can all lead to sideroblastic anaemia. By doing this, acquired sideroblastic anaemia will be avoided.